Erratum to: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (Targ Oncol, 10, 2015 (583-596), 10.1007/s11523-015-0369-6)

Evelyn Despierre; Ignace Vergote; Ryan Anderson; Corneel Coens; Dionyssios Katsaros; Fred R. Hirsch; Bram Boeckx; Marileila Varella-Garcia; Annamaria Ferrero; Isabelle Ray-Coquard; John A. Green; Christopher Steer; Els M.J.J. Berns; Antonio Casado; Diether Lambrechts; Antonio Jimeno

doi:10.1007/s11523-016-0433-x

Erratum to: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (Targ Oncol, 10, 2015 (583-596), 10.1007/s11523-015-0369-6)

Evelyn Despierre, Ignace Vergote, Ryan Anderson, Corneel Coens, Dionyssios Katsaros, Fred R. Hirsch, Bram Boeckx, Marileila Varella-Garcia, Annamaria Ferrero, Isabelle Ray-Coquard, John A. Green, Christopher Steer, Els M.J.J. Berns, Antonio Casado, Diether Lambrechts, Antonio Jimeno

Research output: Contribution to journal › Comment/debate

2 Scopus citations

Abstract

The original version of this article omitted John A. Green and Christopher Steer from the list of authors. The updated list of author names, their affiliations and an updated conflict of interest statement are shown here. Conflict of Interest Marileila Varella-Garcia is co-inventor on a patent held by the University of Colorado to use EGFR copy number as biomarker for selection of lung cancer patients for targeted therapy. John A. Green received funding for the sample collection and coordination of the samples in the UK (NCRI) from Cancer Research UK. Evelyn Despierre, Ignace Vergote, Ryan Anderson, Corneel Coens, Dionyssios Katsaros, Fred R. Hirsch, Bram Boeckx, Annamaria Ferrero, Isabelle Ray-Coquard, Christopher Steer, Els MJJ Berns, Antonio Casado, Diether Lambrechts, and Antonio Jimeno declare no conflict of interest.

Original language	English
Pages (from-to)	429
Number of pages	1
Journal	Targeted Oncology
Volume	11
Issue number	3
DOIs	https://doi.org/10.1007/s11523-016-0433-x
State	Published - 1 Jun 2016
Externally published	Yes

Access to Document

10.1007/s11523-016-0433-x

Fingerprint

Dive into the research topics of 'Erratum to: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (Targ Oncol, 10, 2015 (583-596), 10.1007/s11523-015-0369-6)'. Together they form a unique fingerprint.

Cite this

Despierre, E., Vergote, I., Anderson, R., Coens, C., Katsaros, D., Hirsch, F. R., Boeckx, B., Varella-Garcia, M., Ferrero, A., Ray-Coquard, I., Green, J. A., Steer, C., Berns, E. M. J. J., Casado, A., Lambrechts, D., & Jimeno, A. (2016). Erratum to: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (Targ Oncol, 10, 2015 (583-596), 10.1007/s11523-015-0369-6). Targeted Oncology, 11(3), 429. https://doi.org/10.1007/s11523-016-0433-x

Despierre, Evelyn ; Vergote, Ignace ; Anderson, Ryan et al. / Erratum to : Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (Targ Oncol, 10, 2015 (583-596), 10.1007/s11523-015-0369-6). In: Targeted Oncology. 2016 ; Vol. 11, No. 3. pp. 429.

@article{5d47a432e1b247f48e450cd124dcbce4,

title = "Erratum to: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (Targ Oncol, 10, 2015 (583-596), 10.1007/s11523-015-0369-6)",

abstract = "The original version of this article omitted John A. Green and Christopher Steer from the list of authors. The updated list of author names, their affiliations and an updated conflict of interest statement are shown here. Conflict of Interest Marileila Varella-Garcia is co-inventor on a patent held by the University of Colorado to use EGFR copy number as biomarker for selection of lung cancer patients for targeted therapy. John A. Green received funding for the sample collection and coordination of the samples in the UK (NCRI) from Cancer Research UK. Evelyn Despierre, Ignace Vergote, Ryan Anderson, Corneel Coens, Dionyssios Katsaros, Fred R. Hirsch, Bram Boeckx, Annamaria Ferrero, Isabelle Ray-Coquard, Christopher Steer, Els MJJ Berns, Antonio Casado, Diether Lambrechts, and Antonio Jimeno declare no conflict of interest.",

author = "Evelyn Despierre and Ignace Vergote and Ryan Anderson and Corneel Coens and Dionyssios Katsaros and Hirsch, {Fred R.} and Bram Boeckx and Marileila Varella-Garcia and Annamaria Ferrero and Isabelle Ray-Coquard and Green, {John A.} and Christopher Steer and Berns, {Els M.J.J.} and Antonio Casado and Diether Lambrechts and Antonio Jimeno",

note = "Publisher Copyright: {\textcopyright} Springer International Publishing Switzerland 2016.",

year = "2016",

month = jun,

day = "1",

doi = "10.1007/s11523-016-0433-x",

language = "English",

volume = "11",

pages = "429",

journal = "Targeted Oncology",

issn = "1776-2596",

publisher = "Springer Paris",

number = "3",

}

Despierre, E, Vergote, I, Anderson, R, Coens, C, Katsaros, D, Hirsch, FR, Boeckx, B, Varella-Garcia, M, Ferrero, A, Ray-Coquard, I, Green, JA, Steer, C, Berns, EMJJ, Casado, A, Lambrechts, D & Jimeno, A 2016, 'Erratum to: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (Targ Oncol, 10, 2015 (583-596), 10.1007/s11523-015-0369-6)', Targeted Oncology, vol. 11, no. 3, pp. 429. https://doi.org/10.1007/s11523-016-0433-x

Erratum to: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (Targ Oncol, 10, 2015 (583-596), 10.1007/s11523-015-0369-6). / Despierre, Evelyn; Vergote, Ignace; Anderson, Ryan et al.
In: Targeted Oncology, Vol. 11, No. 3, 01.06.2016, p. 429.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Erratum to

T2 - Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (Targ Oncol, 10, 2015 (583-596), 10.1007/s11523-015-0369-6)

AU - Despierre, Evelyn

AU - Vergote, Ignace

AU - Anderson, Ryan

AU - Coens, Corneel

AU - Katsaros, Dionyssios

AU - Hirsch, Fred R.

AU - Boeckx, Bram

AU - Varella-Garcia, Marileila

AU - Ferrero, Annamaria

AU - Ray-Coquard, Isabelle

AU - Green, John A.

AU - Steer, Christopher

AU - Berns, Els M.J.J.

AU - Casado, Antonio

AU - Lambrechts, Diether

AU - Jimeno, Antonio

PY - 2016/6/1

Y1 - 2016/6/1

N2 - The original version of this article omitted John A. Green and Christopher Steer from the list of authors. The updated list of author names, their affiliations and an updated conflict of interest statement are shown here. Conflict of Interest Marileila Varella-Garcia is co-inventor on a patent held by the University of Colorado to use EGFR copy number as biomarker for selection of lung cancer patients for targeted therapy. John A. Green received funding for the sample collection and coordination of the samples in the UK (NCRI) from Cancer Research UK. Evelyn Despierre, Ignace Vergote, Ryan Anderson, Corneel Coens, Dionyssios Katsaros, Fred R. Hirsch, Bram Boeckx, Annamaria Ferrero, Isabelle Ray-Coquard, Christopher Steer, Els MJJ Berns, Antonio Casado, Diether Lambrechts, and Antonio Jimeno declare no conflict of interest.

AB - The original version of this article omitted John A. Green and Christopher Steer from the list of authors. The updated list of author names, their affiliations and an updated conflict of interest statement are shown here. Conflict of Interest Marileila Varella-Garcia is co-inventor on a patent held by the University of Colorado to use EGFR copy number as biomarker for selection of lung cancer patients for targeted therapy. John A. Green received funding for the sample collection and coordination of the samples in the UK (NCRI) from Cancer Research UK. Evelyn Despierre, Ignace Vergote, Ryan Anderson, Corneel Coens, Dionyssios Katsaros, Fred R. Hirsch, Bram Boeckx, Annamaria Ferrero, Isabelle Ray-Coquard, Christopher Steer, Els MJJ Berns, Antonio Casado, Diether Lambrechts, and Antonio Jimeno declare no conflict of interest.

UR - http://www.scopus.com/inward/record.url?scp=84964042584&partnerID=8YFLogxK

U2 - 10.1007/s11523-016-0433-x

DO - 10.1007/s11523-016-0433-x

M3 - Comment/debate

AN - SCOPUS:84964042584

SN - 1776-2596

VL - 11

SP - 429

JO - Targeted Oncology

JF - Targeted Oncology

IS - 3

ER -

Despierre E, Vergote I, Anderson R, Coens C, Katsaros D, Hirsch FR et al. Erratum to: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (Targ Oncol, 10, 2015 (583-596), 10.1007/s11523-015-0369-6). Targeted Oncology. 2016 Jun 1;11(3):429. doi: 10.1007/s11523-016-0433-x